$1.09 Billion is the total value of Sofinnova Investments, Inc.'s 163 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 104.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Buy | Ascendis Pharma A/Sadr | $126,645,000 | +7.8% | 1,099,824 | +10.1% | 11.64% | +2.7% |
| NXTC | New | Nextcure, Inc | $37,777,000 | – | 2,521,856 | +100.0% | 3.47% | – |
| KRTX | New | Karuna Therapeutics, Inc. | $34,622,000 | – | 1,729,352 | +100.0% | 3.18% | – |
| PTCT | New | PTC Therapeutics Inc | $16,601,000 | – | 368,903 | +100.0% | 1.52% | – |
| NVO | Buy | Novo Nordisk A/Sadr | $16,521,000 | +27.5% | 323,697 | +30.7% | 1.52% | +21.5% |
| NBIX | Buy | Neurocrine Biosciences Inc | $13,159,000 | +32.9% | 155,860 | +38.7% | 1.21% | +26.6% |
| HALO | Buy | Halozyme Therapeutics Inc | $11,858,000 | +83.5% | 690,199 | +72.0% | 1.09% | +75.0% |
| HRTX | Buy | Heron Therapeutics Inc | $11,474,000 | +100.9% | 617,185 | +164.1% | 1.05% | +91.6% |
| TGTX | Buy | TG Therapeutics Inc | $10,911,000 | +285.7% | 1,261,384 | +258.5% | 1.00% | +267.4% |
| RETA | Buy | Reata Pharmaceuticals Inc | $10,901,000 | +96.1% | 115,536 | +77.7% | 1.00% | +86.9% |
| XLRN | New | Acceleron Pharma Inc | $9,902,000 | – | 241,043 | +100.0% | 0.91% | – |
| MGNX | Buy | MacroGenics Inc | $9,341,000 | -0.8% | 550,443 | +5.1% | 0.86% | -5.5% |
| VRTX | New | Vertex Pharmaceuticals Inc | $9,225,000 | – | 50,301 | +100.0% | 0.85% | – |
| Buy | MorphoSys AG | $9,231,000 | +46.2% | 96,135 | +38.6% | 0.85% | +39.5% | |
| New | Amgen Incput | $9,214,000 | – | 50,000 | +100.0% | 0.85% | – | |
| New | Allergan plccall | $8,372,000 | – | 50,000 | +100.0% | 0.77% | – | |
| BMY | New | Bristol-Myers Squibb Co | $7,884,000 | – | 173,849 | +100.0% | 0.72% | – |
| BMRN | Buy | Biomarin Pharmaceutical Inc | $7,272,000 | +342.6% | 84,896 | +359.0% | 0.67% | +322.8% |
| DERM | Buy | Dermira Inc | $6,309,000 | -3.7% | 659,882 | +36.4% | 0.58% | -8.2% |
| INCY | Buy | Incyte Corp | $5,914,000 | +29.5% | 69,612 | +31.1% | 0.54% | +23.4% |
| ORTX | Buy | Orchard Therapeutics PLCadr | $5,113,000 | +3.6% | 365,469 | +32.4% | 0.47% | -1.3% |
| KDMN | Buy | Kadmon Holdings Inc | $4,540,000 | +2.9% | 2,204,202 | +31.8% | 0.42% | -1.9% |
| New | Bristol-Myers Squibb Cocall | $4,534,000 | – | 100,000 | +100.0% | 0.42% | – | |
| ACAD | New | ACADIA Pharmaceuticals Inc | $4,159,000 | – | 155,576 | +100.0% | 0.38% | – |
| ZYME | New | Zymeworks Inc | $4,137,000 | – | 188,057 | +100.0% | 0.38% | – |
| AKBA | Buy | Akebia Therapeutics Inc | $4,106,000 | -3.0% | 848,356 | +64.2% | 0.38% | -7.6% |
| QURE | New | Uniqure NVcall | $3,908,000 | – | 50,000 | +100.0% | 0.36% | – |
| OTIC | Buy | Otonomy Inc | $3,679,000 | +36.6% | 1,337,568 | +30.6% | 0.34% | +30.0% |
| FOMX | Buy | Foamix Pharmaceuticals Ltd | $2,655,000 | -14.9% | 1,115,810 | +34.1% | 0.24% | -18.9% |
| XBIT | Buy | XBiotech Inc | $2,515,000 | -12.7% | 331,811 | +26.9% | 0.23% | -16.9% |
| New | Zogenix Inccall | $2,389,000 | – | 50,000 | +100.0% | 0.22% | – | |
| New | Intra-Cellular Therapies Inccall | $2,271,000 | – | 175,000 | +100.0% | 0.21% | – | |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $2,260,000 | +101.6% | 242,729 | +13.8% | 0.21% | +92.6% |
| New | Deciphera Pharmaceuticals Incput | $2,258,000 | – | 100,100 | +100.0% | 0.21% | – | |
| ADVM | Buy | Adverum Biotechnologies Inc | $2,225,000 | +166.5% | 187,059 | +17.5% | 0.20% | +155.0% |
| ABBV | New | AbbVie Inc | $2,103,000 | – | 28,911 | +100.0% | 0.19% | – |
| CALA | New | Calithera Biosciences Inc | $2,066,000 | – | 529,839 | +100.0% | 0.19% | – |
| OSMT | Buy | Osmotica Pharmaceuticals PLC | $1,996,000 | +119.1% | 525,198 | +107.5% | 0.18% | +108.0% |
| CLVS | Buy | Clovis Oncology Inc | $1,864,000 | +12.7% | 125,303 | +88.0% | 0.17% | +7.5% |
| ITCI | New | Intra-Cellular Therapies Inc | $1,635,000 | – | 125,955 | +100.0% | 0.15% | – |
| BCRX | New | BioCryst Pharmaceuticals Inc | $1,616,000 | – | 426,400 | +100.0% | 0.15% | – |
| ACOR | New | Acorda Therapeutics Inc | $1,488,000 | – | 194,036 | +100.0% | 0.14% | – |
| FTSV | New | Forty Seven Inc | $1,259,000 | – | 118,803 | +100.0% | 0.12% | – |
| APLT | New | Applied Therapeutics Inc | $1,170,000 | – | 142,004 | +100.0% | 0.11% | – |
| AUTL | New | Autolus Therapeutics PLCadr | $1,059,000 | – | 65,780 | +100.0% | 0.10% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.